Nanoparticles for Targeted Drug Delivery in Heart Failure

Area of Science:

• Cardiovascular Nanomedicine
• Heart Failure Pathophysiology
• Drug Delivery Systems

Background:

• Heart failure causes significant global morbidity and mortality despite guideline-directed medical therapy.
• Nanoparticle-based drug delivery shows promise but requires addressing pharmacological barriers for clinical relevance.
• Existing therapies often face pharmacokinetic and biodistribution constraints.

Purpose of the Study:

• To present a framework for evaluating the therapeutic value of nanomedicine in heart failure.
• To define conditions under which nanotechnology offers meaningful advantages over conventional delivery.
• To guide the translation of nanomedicine from preclinical models to clinical application in heart failure.

Main Methods:

• Review of nanoparticle platforms (lipid-based, polymeric) in cardiovascular applications.
• Contextualization of nanomedicine across key heart failure pathophysiological domains.
• Proposal of three criteria for translational relevance of nanomedicine.

Main Results:

• Nanomedicine can enable targeted delivery of potent therapies limited by delivery constraints.
• Key pathophysiological targets include fibrosis (TGF-β), inflammation (IL-1β, TNF-α), oxidative stress, and regenerative/gene therapies.
• Three criteria for translational relevance were proposed: targetable microenvironment, delivery-limited agent, and demonstrable clinical advantage.

Conclusions:

• Nanomedicine should be viewed as an enabling platform, not a replacement for guideline-directed medical therapy.
• Clinical translation of nanomedicine for heart failure is limited, shifting focus to therapeutic necessity.
• Nanomedicine's role is as a precision adjunct, ensuring targeted delivery to the myocardium at the right time.